Overview
In the European Union, peptides intended for human therapeutic use are regulated as medicinal products, not as a separate 'research chemical' category: no medicine may be placed on the EU market without a marketing authorisation granted centrally by the European Medicines Agency or by a national authority. Established peptide drugs such as the semaglutide-class GLP-1 receptor agonists and growth-hormone products are authorised but classified as prescription-only, and injectable products are normally prescription-only by default under the EU classification criteria. Peptides sold as 'research use only' (e.g. BPC-157, TB-500) have no EU marketing authorisation, so offering them for human use, advertising them, or selling them online outside licensed pharmacies is unlawful, and EMA and the Heads of Medicines Agencies issued a joint warning in September 2025 about a sharp rise in illegal GLP-1 products sold online. Personal importation is not fully harmonised at EU level and is governed by national medicines and customs rules, which typically permit only limited personal quantities of lawfully obtained medicines.
Key Points
- Any peptide product intended as a medicine must hold a marketing authorisation from either the European Medicines Agency or a national authority before it can be offered for sale anywhere in the EU. [1]
- Under the EU classification criteria in Directive 2001/83/EC, parenteral (injectable) products — the usual form for peptides — should normally be subject to medical prescription. [2]
- GLP-1 receptor agonist peptides such as semaglutide, liraglutide and tirzepatide are prescription-only medicines in the EU, and in September 2025 EMA and the Heads of Medicines Agencies warned of a sharp rise in unauthorised versions advertised and sold online. [3]
- EU regulators have taken concrete enforcement and alert action on peptide products: falsified pre-filled Ozempic (semaglutide) pens traced to Austrian and German wholesalers were detected in the EU and UK, and national agencies stressed that no legal generic versions exist and that the products cannot be bought legally without a prescription. [4]
- Under the Falsified Medicines Directive 2011/62/EU only licensed pharmacies and approved retailers may offer medicines for sale, including legitimate sale over the internet, which makes typical 'research peptide' web shops selling for human use unlawful supply channels. [5]
- Pharmacy compounding of peptides is possible only through the narrow exemptions in Directive 2001/83/EC for a medicinal product prepared in a pharmacy against a prescription for an individual patient (magistral formula) or in accordance with a pharmacopoeia (officinal formula). [6]
- Personal importation is handled by national medicines and customs law rather than a single EU-wide peptide rule; Germany's customs administration, for example, allows travellers to bring in medicinal products only in quantities matching usual personal need, defined as a maximum three-month supply at the recommended dose. [7]
- No EU-level source was found placing BPC-157, TB-500 or similar 'research' peptides on a narcotics/controlled-substance schedule — the EU drug-control instruments identified address new psychoactive substances rather than therapeutic peptides — so the statement that these peptides are unauthorised medicines rather than scheduled drugs reflects inference from the medicines-authorisation framework above, not a direct peptide-specific source. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)